Mitochondrial Medicine Overview

Principles

Definition

Mitochondrial medicine is a multidisciplinary academic field dedicated to investigating the fundamental roles of mitochondria in cellular physiology, energy metabolism, quality control, signaling, and their intricate involvement in the pathogenesis of human diseases. This research encompasses the study of mitochondrial genetics (mtDNA and nDNA), biochemical pathways like oxidative phosphorylation, and the development of diagnostic and therapeutic approaches targeting mitochondrial dysfunction to restore health.

Ontological type

Mitochondrial Genetics

Diagnostic Strategies

Therapeutic Approaches

Key developments

Key Figures

Bioenergetics and Genetics era

Massimo Zeviani [1], affiliated with Columbia University [3] and the University of Padua [4] in this era, helped illuminate mitochondrial genetics and bioenergetics by co-authoring Deletions of mitochondrial DNA in Kearns-Sayre syndrome [7] and Fatal infantile mitochondrial myopathy and renal dysfunction caused by cytochrome c oxidase deficiency: Immunological studies in a new patient [8]. These contributions clarified that mtDNA deletions [7] and COX deficiency immunology [8] underlie disease pathogenesis and helped integrate mitochondrial genome biology with energy metabolism during this era. S. DiMauro [2], active at The University of Texas Southwestern Medical Center [5] and the University of Pennsylvania [6] in this era, co-authored the Deletions of mitochondrial DNA in Kearns-Sayre syndrome [7], a finding that anchored the genetic basis of mitochondrial disease. This collaboration between Zeviani [1] and DiMauro [2], through mtDNA deletions [7] and mitochondrial immunology [8], helped establish diagnostic criteria and mechanistic links between genome maintenance and tissue bioenergetics, shaping the field's trajectory in this era.

Heteroplasmy and Network Dynamics era

Johan Auwerx[1], with affiliations at Harvard University[3] and the University of California, San Francisco[4], figures prominently in this era. His key contribution in this era is the 2006 paper 'Resveratrol Improves Mitochondrial Function and Protects against Metabolic Disease by Activating SIRT1 and PGC-1α' [6], which demonstrated how resveratrol can activate mitochondrial biogenesis pathways to enhance function and mitigate metabolic disease, thereby illuminating mitochondrial control and network dynamics. Markku Laakso[2], with affiliations at the University of California, San Francisco[4] and The University of Texas Health Science Center at San Antonio[5], contributes to the era's investigation into heteroplasmy and network dynamics. His contribution includes co-authoring the 2006 paper 'Resveratrol Improves Mitochondrial Function and Protects against Metabolic Disease by Activating SIRT1 and PGC-1α' [6], helping to establish a mechanistic link between metabolic regulation and mitochondrial variability in disease.

Mitochondrial Targeted Therapies era

Jun Wang [1], affiliated with Harvard University [3] and the Massachusetts Institute of Technology [4], stands as a central figure in mitochondrial medicine during this era. His key contribution in this era is the paper Mitochondrial outer-membrane protein FUNDC1 mediates hypoxia-induced mitophagy in mammalian cells [7], a discovery that links mitoquality control to cellular responses under low oxygen and informs strategies to restore energetic capacity in disease. Quan Chen [2], associated with Université Paris-Sud [5] and the Icahn School of Medicine at Mount Sinai [6], exemplifies the translational breadth of mitochondrial-targeted research in this period. His key contribution centers on the same paper Mitochondrial outer-membrane protein FUNDC1 mediates hypoxia-induced mitophagy in mammalian cells [7], underscoring how precise mitophagy modulation can support energy homeostasis and immunometabolic signaling in targeted therapies.